Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluconazole + tinidazole is a fixed-dose combination anti-infective medication developed by Chem Med Pharmaceuticals. It combines fluconazole, a triazole antifungal, with tinidazole, a nitroimidazole derivative. Fluconazole works by inhibiting the fungal enzyme lanosterol 14-alpha demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. Tinidazole acts as an antiprotozoal and antibacterial agent; it is reduced within the target organism to form free radicals that cause DNA strand breakage and inhibit nucleic acid synthesis. This combination is primarily indicated for the treatment of mixed vaginal infections, such as those involving Candida species, Trichomonas vaginalis, and anaerobic bacteria. It is administered orally, typically as a single dose or a short course, and is approved for use in treating various forms of vaginitis and associated fungal or protozoal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluconazole + tinidazole.